Cholinesterase is Associated With Prognosis and Response to Chemotherapy in Advanced Gastric Cancer
Authors:
Open Access
- 25 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 580800
Abstract
Background: Cholinesterase (CHE) is a routine serum biomarker in gastric cancer (GC). However, little research has been done on its clinical value in advanced GC. In addition, it is not clear whether it can be used as biomarker for the response and prognosis of advanced GC patients.Methods: Between Jan. 2013 and Dec. 2016, a total of 150 patients with advanced GC treated with first-line chemotherapy were admitted to Changzhou Tumor Hospital Affiliated to Soochow University. We retrospectively identified serum CHE level on the day before chemotherapy and at the end of chemotherapy and abstracted clinicopathologic features and treatment outcomes. Univariate and multivariate survival analyses were performed to assess the relationship between serum CHE levels and progression-free survival (PFS) and overall survival (OS).Results: A total of 150 advanced GC patients were included and divided into serum level ≥5,000 IU/L and serum level p = 0.006), poorer OS (HR, 1.76; 95% CI, 1.228–2.515; p = 0.002) and trend of poorer response (HR, 0.56; 95% CI, 0.272–1.129; p = 0.104). In univariate and multivariate logistic regression analysis, only liver metastasis and PS score were significantly associated with objective response (p < 0.05). The medium PFS was 8.0 months in patients with post-treatment CHE increased vs. 3.8 months in patients with CHE decreased after chemotherapy (HR, 1.82; 95% CI 1.28–2.57; p = 0.0002). The medium OS was 13.1 months in patients with increased post-treatment CHE vs. 8.1 months in patients with decreased post-treatment CHE (HR, 1.87; 95% CI 1.29–2.71; p = 0.0002).Conclusion: Advanced GC with CHE levels below 5,000 IU/L was significantly associated with poor PFS and OS. The results suggested that CHE analysis before chemotherapy was a promising prognostic marker for advanced GC.Keywords
This publication has 15 references indexed in Scilit:
- The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancerCancer Communications, 2019
- Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancerEuropean Journal of Surgical Oncology, 2016
- Endoscopic prediction of tumor margin and invasive depth in early gastric cancerJournal of Digestive Diseases, 2015
- Cholinesterase activities and biochemical determinations in patients with prostate cancer: Influence of Gleason score, treatment and bone metastasisBiomedicine & Pharmacotherapy, 2012
- Low Serum Level of Cholinesterase at Recurrence of Pancreatic Cancer Is a Poor Prognostic Factor and Relates to Systemic Disorder and Nerve Plexus InvasionPancreas, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations—A Study by the Steering Committee of the European Association for Palliative CareJournal of Clinical Oncology, 2005
- Molecular-pathological prognostic factors of gastric cancer: a reviewGastric Cancer, 2005
- Alterations of serum cholinesterase in patients with gastric cancerWorld Journal of Gastroenterology, 2005
- Attenuation of MPTP‐induced dopaminergic neurotoxicity by TV3326, a cholinesterase‐monoamine oxidase inhibitorJournal of Neurochemistry, 2003